Related Experiment Video

Updated: May 23, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Bevacizumab in endometrial cancer treatment

Matteo Morotti1, Mario Valenzano Menada, Pier Luigi Venturini

  • 1Department of Obstetrics and Gynaecology, University of Genoa, San Martino Hospital, 16132 Genoa, Italy.

Expert Opinion on Biological Therapy
|March 21, 2012
PubMed
Abstract

Insights

Bevacizumab, an antiangiogenic drug, shows promise for treating advanced endometrial cancer (EC). This review explores its mechanism, clinical trials, and future potential in EC management.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Advanced or recurrent endometrial cancer (EC) requires novel therapeutic strategies.
  • Molecular targeted therapies, particularly antiangiogenic drugs, are a key area of research.
  • Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, is a significant antiangiogenic agent.

Purpose of the Study:

  • To review the mechanism of action and clinical trials of bevacizumab in EC.
  • To discuss the rationale for targeting tumor angiogenesis in EC.
  • To summarize preclinical and clinical results of bevacizumab in EC patients.

Main Methods:

  • Literature review of relevant papers and meeting abstracts published up to December 2011.
  • Analysis of preclinical data and clinical trial results for bevacizumab in EC.
  • Synthesis of information regarding the drug's efficacy and safety.

Main Results:

  • Bevacizumab interferes with tumor angiogenesis, a critical process in EC.
  • Clinical trials have provided initial data on bevacizumab's activity in EC patients.
  • The review summarizes key findings from preclinical and clinical studies.

Conclusions:

  • Targeted therapies, including antiangiogenic agents, represent a promising frontier in EC treatment.
  • Bevacizumab is a notable example of an antiangiogenic agent with potential in EC management.
  • Further research and clinical application of bevacizumab are suggested for advanced EC.

More Related Videos

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring08:45

Cerenkov Luminescence Imaging (CLI) for Cancer Therapy Monitoring

Published on: November 13, 2012

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells09:24

Three-dimensional Angiogenesis Assay System using Co-culture Spheroids Formed by Endothelial Colony Forming Cells and Mesenchymal Stem Cells

Published on: September 18, 2019

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...